ProLynx LLC

Basic Information

211 Belgrave Ave
San Francisco, CA, 94117-3851

Company Profile

n/a

Additional Details

Field Value
DUNS: 831183954
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 6


  1. SBIR Phase II: Controlled Drug Release from and Degradation of Hydrogels

    Amount: $742,778.00

    The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is an improvement in public health and quality of life through improved methods of medicinal t ...

    SBIR Phase II 2015 National Science Foundation
  2. SBIR Phase I: Controlled Drug Release from and Degradation of PEG-Hydrogels

    Amount: $150,000.00

    This Small Business Innovation Research Phase I project seeks to develop novel hydrogel drug-delivery systems. We have developed linkers for drug conjugation to circulating macromolecules that release ...

    SBIR Phase I 2013 National Science Foundation
  3. Releasable site-specific attachment of macromolecules to therapeutic peptides

    Amount: $143,958.00

    DESCRIPTION (provided by applicant): Many potent and specific peptides suffer problems of short or sub-optimal duration. A possible solution to such problems involves conjugation to macromolecules suc ...

    SBIR Phase I 2010 Department of Health and Human Services
  4. Releasable attachment of drugs to PEGylated dendrimers

    Amount: $149,650.00

    DESCRIPTION (provided by applicant): We are developing a platform technology that allows predictable, controlled release of drugs from macromolecule-drug conjugates. In one current format, PEG of suff ...

    SBIR Phase I 2010 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government